View Older Stories View More Recent Stories

Mar 30, 2017 07:04AM AbbVie (ABBV) Announces FDA Approval for Addition of Moderate to Severe Fingernail Psoriasis Data to HUMIRA Prescribing Information
Mar 30, 2017 07:00AM U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information
Mar 28, 2017 08:02AM AbbVie (ABBV), M2Gen Announce New Collaboration for ORIEN Avatar Research Program
Mar 28, 2017 08:00AM AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program
Mar 23, 2017 07:45AM Julianne Hough Empowers Women to "Get in the Know" About Endometriosis
Mar 14, 2017 08:03AM AbbVie's (ABBV) G/P Regimen for HCV Granted Priority Review in Japan
Mar 14, 2017 08:00AM AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Mar 1, 2017 08:00AM AbbVie to Present at the Barclays Global Healthcare Conference
Feb 27, 2017 04:00AM AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic
Feb 17, 2017 08:01AM AbbVie (ABBV) Increases Buyback by $5B
Feb 17, 2017 08:00AM AbbVie Announces $5 Billion Increase to Stock Repurchase Program
Feb 16, 2017 12:41PM AbbVie Declares Quarterly Dividend
Feb 15, 2017 08:01AM AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 2, 2017 08:04AM AbbVie (ABBV) Granted FDA Priority Review for Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C
Feb 2, 2017 08:00AM U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jan 27, 2017 07:48AM AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results
Jan 25, 2017 08:06AM AbbVie (ABBV) Initiated Phase 2 Trials for ABBV-8E12 to Treat AD and PSP
Jan 25, 2017 08:00AM AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
Jan 24, 2017 04:00AM European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chron
Jan 19, 2017 07:04AM AbbVie (ABBV) Announces FDA Approval for IMBRUVICA to Treat Specifically Indicated for R/R MZL
Jan 19, 2017 07:00AM U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Jan 10, 2017 09:00AM AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call
Jan 9, 2017 08:05AM AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance
Jan 9, 2017 08:00AM AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science
Jan 9, 2017 07:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japane
Dec 22, 2016 08:00AM AbbVie to Present at the 35th Annual J.P. Morgan Healthcare Conference
Dec 19, 2016 08:03AM AbbVie (ABBV) Submits NDA for Regimen of Glecaprevir/Pibrentasvir to Treat Hepatitis C
Dec 19, 2016 08:00AM AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Dec 6, 2016 10:37AM AbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD
Dec 6, 2016 10:30AM Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication
Dec 6, 2016 06:16AM AbbVie (ABBV) Offers Update on IMBRUVICA Phase 2 in r/r MZL; Median Duration Response Not Reached
Dec 5, 2016 09:15PM New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)
Dec 5, 2016 08:56AM AbbVie (ABBV), the Johns Hopkins University SoM Enter Five-Year Cancer Research Agreement
Dec 5, 2016 08:55AM AbbVie (ABBV), Northwestern University Enter Three-Year Cancer Research Collaboration
Dec 5, 2016 08:55AM AbbVie and Johns Hopkins to Collaborate on Cancer Research
Dec 5, 2016 08:50AM AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement
Dec 5, 2016 06:34AM AbbVie (ABBV) Updates on Five-Year IMBRUVICA Data in CLL/SLL; Strong CR/PR Results Noted
Dec 4, 2016 07:30PM Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma
Dec 3, 2016 07:00PM IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy
Nov 30, 2016 02:00PM AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease
Nov 16, 2016 11:02AM Janssen Announces Significant Data from Two SC Sirukumab Phase 3s as RA Treatment
Nov 16, 2016 08:01AM Regeneron (REGN), Sanofi (SNY) Announce Presentation of Strong Sarilumab Monotherapy Phase 3 Data vs. Humira
Nov 15, 2016 08:00AM AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
Nov 14, 2016 06:13AM AbbVie (ABBV) Receives Positive CHMP Opinion for HUMIRA as HS Treatment
Nov 14, 2016 03:00AM AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Nov 11, 2016 08:06AM AbbVie (ABBV) Updates on Glecaprevir/Pibrentasvir Treatment Regiment in HCV; High SVR12 Rates Noted at 8 Weeks
Nov 11, 2016 08:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C
Nov 4, 2016 01:35PM AbbVie (ABBV) Announces Receipt of FDA Orphan Drug Designation for Veliparib as NSCLC Treatment
Nov 4, 2016 01:33PM AbbVie Receives FDA Orphan Drug Designation for Investigational Medicine Veliparib for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Nov 3, 2016 09:00AM AbbVie to Showcase Growing Oncology Portfolio and Commitment to Treating Blood Cancers at the 2016 American Society of Hematology Annual Meeting
View More Recent Stories View Older Stories